IgA Nephropathy Treatment with Sibeprenlimab
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on February 23rd, 2024
|
IgA nephropathy stands as the predominant cause of glomerulonephritis. Kidney impairment arises from the formation of immune complexes, orchestrated by autoantibodies that target galactose-deficient IgA antibodies. To explore treatment avenues, a study investigated the efficacy of Sibeprenlimab in IgA nephropathy management by inhibiting APRIL, a crucial protein involved in regulating B-cell immune response.
The phase 2 clinical trial involved 155 patients diagnosed with IgA nephropathy, confirmed through biopsy. These patients exhibited a 24-hour urinary protein-to-creatinine ratio of at least 0.75 and an estimated glomerular filtration rate (eGFR) of at least 30 ml per minute per 1.73 m^2 of body surface area. Serum IgG levels were a minimum of 700 mg per deciliter, while IgM and IgA levels were at least 37 and 70 mg per deciliter, respectively. Participants were randomly allocated to receive intravenous treatment with either Sibeprenlimab or placebo. Sibeprenlimab was administered at three different dose levels: 2, 4, and 8 mg per kilogram of body weight. After 12 months of treatment, a notable decrease in galactose-deficient IgA levels was observed in the Sibeprenlimab-treated groups compared to the placebo group. Moreover, the placebo group exhibited a 20% reduction in urinary protein-to-creatinine ratio from baseline, while those in the 2-mg group experienced a 47% reduction, and approximately 60% reduction was observed in the other two groups. Additionally, participants in the placebo group showed more rapid deterioration in kidney function, as measured by eGFR, compared to those in the Sibeprenlimab group, although significant improvement in eGFR was limited in the Sibeprenlimab group.
The phase 2 clinical trial involved 155 patients diagnosed with IgA nephropathy, confirmed through biopsy. These patients exhibited a 24-hour urinary protein-to-creatinine ratio of at least 0.75 and an estimated glomerular filtration rate (eGFR) of at least 30 ml per minute per 1.73 m^2 of body surface area. Serum IgG levels were a minimum of 700 mg per deciliter, while IgM and IgA levels were at least 37 and 70 mg per deciliter, respectively. Participants were randomly allocated to receive intravenous treatment with either Sibeprenlimab or placebo. Sibeprenlimab was administered at three different dose levels: 2, 4, and 8 mg per kilogram of body weight. After 12 months of treatment, a notable decrease in galactose-deficient IgA levels was observed in the Sibeprenlimab-treated groups compared to the placebo group. Moreover, the placebo group exhibited a 20% reduction in urinary protein-to-creatinine ratio from baseline, while those in the 2-mg group experienced a 47% reduction, and approximately 60% reduction was observed in the other two groups. Additionally, participants in the placebo group showed more rapid deterioration in kidney function, as measured by eGFR, compared to those in the Sibeprenlimab group, although significant improvement in eGFR was limited in the Sibeprenlimab group.